DEL VECCHIO, SILVANA
 Distribuzione geografica
Continente #
AS - Asia 5.367
NA - Nord America 4.788
EU - Europa 3.213
SA - Sud America 592
Continente sconosciuto - Info sul continente non disponibili 197
AF - Africa 171
OC - Oceania 6
Totale 14.334
Nazione #
US - Stati Uniti d'America 4.598
SG - Singapore 2.528
RU - Federazione Russa 1.473
VN - Vietnam 940
CN - Cina 931
IT - Italia 513
BR - Brasile 459
HK - Hong Kong 436
DE - Germania 204
FR - Francia 192
UA - Ucraina 164
FI - Finlandia 149
IE - Irlanda 121
CA - Canada 99
BD - Bangladesh 97
GB - Regno Unito 91
IN - India 83
SE - Svezia 80
JP - Giappone 74
NL - Olanda 65
BE - Belgio 58
AR - Argentina 57
MX - Messico 50
CI - Costa d'Avorio 49
KR - Corea 42
ZA - Sudafrica 37
PH - Filippine 30
IQ - Iraq 29
TH - Thailandia 24
PL - Polonia 23
AT - Austria 21
EC - Ecuador 21
ID - Indonesia 18
TR - Turchia 17
MA - Marocco 16
TW - Taiwan 15
VE - Venezuela 15
TN - Tunisia 14
CO - Colombia 11
LT - Lituania 11
ES - Italia 10
EG - Egitto 9
PY - Paraguay 9
SA - Arabia Saudita 9
UZ - Uzbekistan 9
DZ - Algeria 8
KZ - Kazakistan 8
PK - Pakistan 8
AE - Emirati Arabi Uniti 7
CL - Cile 7
DO - Repubblica Dominicana 7
HN - Honduras 7
JO - Giordania 6
MY - Malesia 6
NP - Nepal 6
PE - Perù 6
SN - Senegal 6
AZ - Azerbaigian 5
JM - Giamaica 5
KE - Kenya 5
OM - Oman 5
BG - Bulgaria 4
CR - Costa Rica 4
CZ - Repubblica Ceca 4
GH - Ghana 4
IR - Iran 4
IS - Islanda 4
AM - Armenia 3
AU - Australia 3
BO - Bolivia 3
CG - Congo 3
ET - Etiopia 3
GE - Georgia 3
IL - Israele 3
KG - Kirghizistan 3
LB - Libano 3
PA - Panama 3
QA - Qatar 3
RO - Romania 3
TT - Trinidad e Tobago 3
UY - Uruguay 3
AL - Albania 2
AO - Angola 2
BB - Barbados 2
BJ - Benin 2
BZ - Belize 2
DK - Danimarca 2
EU - Europa 2
HU - Ungheria 2
LK - Sri Lanka 2
LV - Lettonia 2
LY - Libia 2
NG - Nigeria 2
NZ - Nuova Zelanda 2
PR - Porto Rico 2
PS - Palestinian Territory 2
RS - Serbia 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
SY - Repubblica araba siriana 2
Totale 14.107
Città #
Singapore 1.172
San Jose 726
Hong Kong 423
Moscow 360
Chandler 322
Ashburn 302
Ho Chi Minh City 271
Beijing 225
Hanoi 204
Jacksonville 201
Santa Clara 173
The Dalles 142
Lauterbourg 138
Boston 129
Council Bluffs 128
Naples 126
Princeton 126
Los Angeles 124
Millbury 124
Woodbridge 107
Nanjing 88
Buffalo 72
Wilmington 69
Hefei 68
Tokyo 65
Chicago 58
Amsterdam 53
New York 53
Da Nang 52
Houston 51
Brussels 48
Haiphong 45
Redondo Beach 41
Ottawa 40
Dallas 38
Munich 36
Des Moines 35
Seattle 35
São Paulo 35
Ann Arbor 34
Nanchang 34
Tianjin 33
Phoenix 32
Orem 29
Napoli 28
Hebei 27
Shenyang 26
Nuremberg 25
Frankfurt am Main 24
Milan 23
Dublin 22
Rome 22
Lawrence 21
Changsha 20
Mexico City 20
Jiaxing 19
Brooklyn 18
Norwalk 18
Biên Hòa 17
San Francisco 17
Atlanta 15
Montreal 15
Seoul 15
Toronto 15
Baghdad 14
Hải Dương 14
London 14
Warsaw 14
Boardman 13
Denver 13
Kochi 13
Stockholm 13
Turku 13
Dong Ket 12
Falls Church 12
Chennai 10
Curitiba 10
Helsinki 10
Kronberg 10
Pune 10
Zhengzhou 10
Belo Horizonte 9
Falkenstein 9
Guayaquil 9
Johannesburg 9
Poplar 9
Quận Bình Thạnh 9
Rio de Janeiro 9
Thái Bình 9
Can Tho 8
Guangzhou 8
Kunming 8
Manchester 8
Mumbai 8
Washington 8
Brasília 7
Charlotte 7
Columbus 7
Lappeenranta 7
Tashkent 7
Totale 7.434
Nome #
2-deoxy-2[F-18] fluoro-D-GLUCOSE POSITRON EMISSION TOMOGRAPHY Deauville scale and core-needle biopsy to determine successful management after six doxorubicin, bleomycin, vinblastine and dacarbazine cycles in advanced-stage Hodgkin lymphoma 195
Heterogeneity of SSTR2 expression assessed by 68Ga-DOTATOC PET/CT using coefficient of variation in patients with neuroendocrine tumors 187
Tumor induced osteomalacia: a systematic review and individual patient's data analysis 185
Machine Learning and Texture Analysis of [18F]FDG PET/CT Images for the Prediction of Distant Metastases in Non-Small-Cell Lung Cancer Patients 180
Evaluation of metabolic response with 18F-FDG PET-CT in patients with advanced or recurrent thymic epithelial tumors. 158
Liposomal doxorubicin supercharge-containing front-line treatment in patients with advanced-stage diffuse large B-cell lymphoma or classical Hodgkin lymphoma: Preliminary results of a single-centre phase II study 155
Bone marrow uptake of 99mTc-MIBI in patients with multiple myeloma 154
Prediction of 2-[18F]FDG PET-CT SUVmax for Adrenal Mass Characterization: A CT Radiomics Feasibility Study 151
Diagnosis, Management and Theragnostic Approach of Gastro-Entero-Pancreatic Neuroendocrine Neoplasms 145
Heterogeneity of glycolytic phenotype determined by 18F-FDG PET/CT using coefficient of variation in patients with advanced non-small cell lung cancer 145
Total metabolic tumor volume by 18F-FDG PET/CT for the prediction of outcome in patients with non-small cell lung cancer 144
ATM inhibition blocks glucose metabolism and amplifies the sensitivity of resistant lung cancer cell lines to oncogene driver inhibitors 143
Investigation of integrin expression in cancer stem cells isolated from glioblastoma patients 142
2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography/computed tomography in primary extranodal lymphomas: treatment response evaluation and prognosis 140
Early 18F-FDG uptake as a reliable imaging biomarker of T790M-mediated resistance but not MET amplification in non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors 139
Coefficient of variation in metastatic lymph nodes determined by 18F-FDG PET/CT in patients with advanced NSCLC: combination with coefficient of variation in primary tumors 135
Breast tumor cell invasion and pro-invasive activity of cancer-associated fibroblasts co-targeted by novel urokinase-derived decapeptides 135
Impact of COVID-19 pandemic on 2-[18F]FDG PET/CT imaging work-flow in a single medical institution: comparison among the three Italian waves 134
Distribution of mediastinal lesions across multi-institutional, international, radiology databases 125
Multimodal imaging with 18F-FDG-PET/CT and 111In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma 124
Metabolic tumor volume assessed by 18F-FDG-PET/CT for the prediction of outcome in patients with multiple myeloma 123
Epidermal growth factor (EGFR) and Transferrin (TRFR) receptor upregulation is induced by arabinoside cytosine (ARA-C) on human tumor cells. 122
Functional imaging of multidrug resistant phenotype by 99mTc-MIBI scan in patients with multiple myeloma 122
Oncologia 121
18F-FDG-PET/CT, 99mTc-MIBI and MRI in the prediction of outcome of patients with multiple myeloma: a comparative study 120
FDG-PET/CT imaging during the Covid-19 emergency: a southern Italian perspective 120
Washout of 99mTc-Sestamibi in predicting response to chemotherapy in patients with multiple myeloma. 119
Functional imaging of multidrug resistance in breast cancer. 118
Performance of FDG-PET/CT in solitary pulmonary nodule based on pre-test likelihood of malignancy: results from the ITALIAN retrospective multicenter trial 118
Non-canonical role of PDK1 as a negative regulator of apoptosis through macromolecular complexes assembly at the ER-mitochondria interface in oncogene-driven NSCLC 117
Sphingosine Kinase 1 (SphK1) overespression contributes to cetuximab resistance in human colrectal cancer. 116
Visual and volumetric parameters by 18F-FDG-PET/CT: a head to head comparison for the prediction of outcome in patients with multiple myeloma 116
Neutrophil extracellular traps as an adhesion substrate for different tumor cells expressing RGD-binding integrins. 114
Dynamic roles of neutrophil extracellular traps in cancer cell adhesion and activation of Notch 1-mediated epithelial-to-mesenchymal transition in EGFR-driven lung cancer cells 113
Sestamibi and FDG-PET scans to support diagnosis of jaw osteonecrosis. 112
Bone scintigraphy and SPECT/CT in bisphosphonate-induced osteonecrosis of the jaw 110
Permeabilità bronchiale transepiteliale. Basi funzionali ed implicazioni cliniche. 109
Nuclear imaging in cancer theranostic 108
99mTc-MIBI in the evaluation of breast cancer biology 107
PET/CT in cancer research: from preclinical to clinical applications. 107
18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma 105
F-18-FDG-PET/CT, 99mTC-MIBI and MRI in the evaluation of patients with multiple myeloma 104
18F-FDG-PET/CT, 99mTc-MIBI and MRI in the evaluation of patients with multiple myeloma 103
Detection of focal myeloma lesions by technetium-99m-sestaMIBI scintigraphy. 102
Combined imaging with 18F-FDG-PET/CT and 111In-labeled Octreotide SPECT for evaluation of thymic epithelial tumors 102
99mTc-MIBI uptake in Bcl-2 overexpressing non-Hodgkin's lymphoma patients during drug-induced apoptosis. 101
Coordinate up-regulation of Sp1 DNA-binding activity and urokinase receptor expression in breast carcima 100
99mTc-MIBI in the evaluation of breast cancer biology 100
Brain metastases unresponsive to immunotherapy detected by 18F-FDG-PET/CT in a patient with melanoma 100
Tc99m-sestaMIBI uptake in nonsecretory multiple myeloma 99
Bcl-2 overexpression prevents 99mTc-MIBI uptake in breast cancer cell lines. 99
Gefitinib induction of in vivo detectable signals by Bcl-2/Bcl-xL modulation of inositol trisphosphate receptor type 3. 99
La Medicina Nucleare in Oncologia 98
18F-FDG-PET/CT in the evaluation of bone marrow infiltration in patients with multiple myeloma. 97
99mTc-MIBI uptake in breast cancer cells during early phases of apoptosis induction with Staurosporine 96
Dynamic coupling of 99mTc-MIBI efflux and apoptotic pathway activation in untreated breast cancer patients 95
Scintigraphic detection of multidrug resistance in cancer 95
Detection of leptomeningeal involvement by 18F-FDG-PET/CT in a patient with non-Hodgkin lymphoma 95
What molecular imaging of cancer patients can teach us about COVID-19 94
Integrin-dependent cell adhesion to neutrophil extracellular traps through engagement of fibronectin in neutrophil-like cells 93
Nuclear Imaging of Apoptosis in Animal Tumor Models 92
Urokinase receptor interacts with avb5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer 92
Coefficient of variation and texture analysis of 18F-FDG PET/CT images for the prediction of outcome in patients with multiple myeloma 91
European Association of Nuclear Medicine 91
Brentuximab Vedotin With Adriamycin, Vinblastine, and Dacarbazine for Patients Aged 18-59 Years With Untreated Advanced Stage Classical Hodgkin Lymphoma: The Largest Real-Life Series From Southern Italy Cancer Centers 90
Preclinical imaging in targeted cancer therapies. 89
Radiolabeling approches for cholecystokinin B receptor imaging 89
PET-based volumetric biomarkers for risk stratification of non-small cell lung cancer patients 89
Molecular imaging of tumor microenvironment: challenges and perspectives 88
3'-Deoxy-3'-18F-Fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non–small cell lung cancer 87
SPECT imaging of endoplasmic reticulum-mediated tumor response to gefitinib and erlotinib in lung cancer 87
Detection of colon cancer with radiolabelled monoclonal antibodies. 86
In vitro receptor imaging for characterization of human solid tumors. 85
Combined SPECT/CT and PET/CT for breast imaging 85
Vitronectin binding to urokinase receptor in human breast carcinoma 83
Mammoscintigrafia e carcinoma mammario 83
Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: comparison with urokinase levels. 83
99mTc-MIBI uptake is reduced in Bcl-2 overexpressing MCF-7 breast cancer cells 83
Metabolic Tumor Volume assessed by 18F-FDG-PET/CT in the evaluation of plasma cell mass and prediction of outcome in patients with multiple myeloma. 83
111In-pentetreotide scintigraphy:procedure guidelines for tumor imaging 82
Technetium 99m sestamibi in multiple myeloma 81
Predictive value of technetium-99m sestamibi in patients with multiple myeloma and potential role in the follow-up 81
Evaluation of therapeutic response using iodine-131-B72.3 monoclonal antibody in patients with ovarian carcinoma. 81
Coordinate modulation of glycolytic enzymes and OXPHOS by imatinib in BCR-ABL driven chronic myelogenous leukemia cells. 81
Scintimammography with 99mTc-MIBI versus dynamic MRI forn non-invasive characterization of breast masses 79
Annual Congress of the European Association of Nuclear Medicine Munich 2008 79
Texture Analysis of 68Ga-DOTATOC PET/CT Images for the Prediction of Outcome in Patients with Neuroendocrine Tumors 77
Fractional retention of 99mTc-sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients. 77
Local concentration of folate binding protein GP38 in sections of human ovarian carcinoma by in vitro quantitative autoradiography. 77
MIBI as prognostic factor in breast cancer 76
A new role for nuclear medicine in multiple myeloma. 76
A reversible shift of driver dependence from EGFR to Notch1 in non-small cell lung cancer as a cause of resistance to tyrosine kinase inhibitors. 76
Evaluation of the side effects of chemotherapy and radiotherapy on other organs 75
Avid (67)Ga uptake in multiple myeloma relapsing after bone marrow transplant. 75
Molecular imaging: High-resolution detectors for early diagnosis and therapy monitoring of breast cancer. 75
Use of 99mTc-sestamibi scintigraphy in multiple myeloma 74
Tumor clearance of Technetium 99m-Sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer 74
Endobronchial administration of iodine-131 B72.3 monoclonal antibody in patients with lung cancer. 74
Imaging of αvβ3 expression by a bifunctional chimeric RGD peptide not cross-reacting with αvβ5. 74
Reversal of Warburg effect and reactivation of oxidative phosphorylation by differential inhibition of EGFR signaling pathways in non-small cell lung cancer. 74
Totale 10.579
Categoria #
all - tutte 52.727
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 52.727


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022711 0 0 7 1 10 29 11 22 114 38 145 334
2022/2023769 162 57 14 64 95 88 4 71 122 48 38 6
2023/2024616 43 82 65 41 41 22 23 83 24 20 119 53
2024/20253.490 215 273 11 41 84 151 445 215 251 385 1.137 282
2025/20266.845 691 414 677 559 1.325 272 627 488 947 455 167 223
2026/2027426 153 233 40 0 0 0 0 0 0 0 0 0
Totale 14.334